AM-003 is under clinical development by Aummune Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AM-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AM-003 overview
AM-003 is under development for the treatment of advanced and metastatic solid tumors like head and neck cancers, pancreatic cancer, lung cancer, ovarian cancer, thyroid cancers, soft tissue sarcoma, colorectal cancers, melanoma and non-melanoma skin cancer. The therapeutic candidate is a bispecific personalized aptamer. The drug candidate comprises of cytosine- phosphate guanine (CpG) nucleotides and acts by targeting toll like receptor 9 (TLR9). It is administered through intratumor route.
Aummune Therapeutics overview
Aummune Therapeutics a biotechnology research company which develops an individual drug-customization platform to match and produce a patient-specific parameters in specific way. Aummune Therapeutics is headquartered in Tel Aviv-Yafo, Tel Aviv, Israel.
For a complete picture of AM-003’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
